Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.

@article{Siemers2005SafetyTA,
  title={Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.},
  author={Eric R. Siemers and Michael Skinner and R. A. Dean and Celedon R. Gonzales and Julie Satterwhite and Martin R. Farlow and Daniel Ness and Patrick C. May},
  journal={Clinical neuropharmacology},
  year={2005},
  volume={28 3},
  pages={126-32}
}
Amyloid beta (Abeta) may play a central role in the pathogenesis of Alzheimer disease. A functional gamma-secretase inhibitor, LY450139, was developed that inhibits Abeta formation in whole cell assays, transgenic mice, and beagle dogs. The authors wished to determine the safety and tolerability of this drug, and the reduction of Abeta in plasma and cerebrospinal fluid (CSF) after multiple doses. Volunteer subjects (N = 37) were studied using doses from 5 to 50 mg/day given for 14 days. Plasma… CONTINUE READING
69 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 69 extracted citations

Similar Papers

Loading similar papers…